SCHEMBL4712982

SCHEMBL4712982

O=C(O)c1c(-c2ccccc2)c2cc(Cl)ccc2c(=O)n1C(Cc1ccccc1)C1=COCO1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 13/20 0.46
TACR1 P25103 1/20 0.39
DPP4 P27487 5/20 0.38
EDNRA P25101 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4710293 0.91 MAPK8 (0.50) MAPK8
SCHEMBL4712591 0.89 MAPK8 (0.47) MAPK8DPP4
SCHEMBL4710456 0.84 MAPK8 (0.47) MAPK8DPP4
SCHEMBL4709448 0.82 MAPK8 (0.57) MAPK8DPP4
SCHEMBL4712333 0.82 MAPK8 (0.47) MAPK8
SCHEMBL4709851 0.81 MAPK8 (0.57) MAPK8
SCHEMBL4710878 0.81 MAPK8 (0.51) MAPK8
SCHEMBL4710284 0.80 MAPK8 (0.45) MAPK8DPP4
SCHEMBL1518850 0.80 MAPK8 (0.57) MAPK8
SCHEMBL1518800 0.80 MAPK8 (0.47) MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402595-B2 Enzyme inhibitors with isoquinolinone structures TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-22 US disclosed
US-20050148624-A1 Jnk inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-07-07 US disclosed
EP-1484320-A1 JNK INHIBITOR Takeda Chemical Industries, Ltd. (JP) 2004-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148624-A1 Jnk inhibitor MAPK3, MAPKAPK3, MAPK1 MAPK8 5/4885TACR1 4613/4885DPP4 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.